COMMUNIQUÉS West-GlobeNewswire

Artios Pharma Announces Details of Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025
15/04/2025
CAMBRIDGE, United Kingdom and NEW YORK, April 15, 2025 – Artios Pharma Limited (“Artios”), a clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, today announced that the [...]
RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development
15/04/2025
SOUTH SAN FRANCISCO, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing [...]
Predictive Oncology Develops Novel Approach to Identifying Clinically Viable Abandoned Drugs
15/04/2025
New indications discovered by applying active machine learning and using samples from the company’s vast biobank of live-cell tumors specimens Builds upon Predictive’s biomarker discovery platform to select targeted [...]
Neuphoria Provides a Review of 2024 and Highlights 2025 Plans
15/04/2025
Initiation by Merck of a Phase 2 trial in Alzheimer’s disease with partnered α7 nicotinic acetylcholine receptor PAM MK-1167 highlights company’s pipeline diversification beyond BNC210 US $15M milestone payment from [...]
Alberta Cancer Foundation partners with CDL Cancer to advance oncology innovation
15/04/2025
CALGARY, Alberta, April 15, 2025 (GLOBE NEWSWIRE) -- Creative Destruction Lab (CDL) is pleased to announce that the Alberta Cancer Foundation (ACF) is joining the CDL Cancer program. This partnership brings together a [...]
Tectonic Therapeutic to Present Phase 1b Data for TX45 at European Society of Cardiology Heart Failure 2025
15/04/2025
Late-breaking oral presentation to include full Phase 1b results for TX45 in the Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”) cohort WATERTOWN, Mass., April 15, 2025 ( [...]
FDA Clears Ceribell’s Clarity™ Algorithm for Pediatric Patients, Making Ceribell the First and Only FDA-Cleared AI Technology for Detection of Electrographic Seizures in Patients Ages 1 Year and Older
15/04/2025
Powered by Clarity, the Ceribell System will enable rapid, bedside detection, diagnosis and treatment of non-convulsive seizures in children experiencing neurological emergencies SUNNYVALE, Calif., April 15, 2025 (GLOBE [...]
Hydreight Technologies Expands GLP-1 Telehealth Suite with Launch of Liraglutide on VSDHOne Platform
15/04/2025
Liraglutide Offers Long-Term Stability and Expands Hydreight’s Comprehensive GLP-1 Weight Management Portfolio VANCOUVER, British Columbia and LAS VEGAS, April 15, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (“ [...]
Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates
15/04/2025
WARRINGTON, Pa., April 15, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for [...]
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2025 Congress
15/04/2025
NORCROSS, Ga., April 15, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today [...]
Chemomab Announces New Medical and Clinical Appointments
15/04/2025
David M. Weiner, MD, Rejoins Chemomab as Interim Chief Medical Officer, Bringing Extensive Biotechnology and Pharmaceutical Industry R&D, Drug Development and Strategic Experience Jack Lawler, Who Oversaw the [...]
Lisata Therapeutics Announces Research License with Catalent
15/04/2025
Catalent to evaluate certepetide with its SMARTag® antibody-drug conjugate platform BASKING RIDGE, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a [...]
Processa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025
15/04/2025
HANOVER, Md., April 15, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer [...]
Extendicare Announces April 2025 Dividend of C$0.042 per Share
15/04/2025
MARKHAM, Ontario, April 15, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.042 per common share of the Company (the “Common [...]
ORYZON Announces First Patient Dosed in NCI-Sponsored Phase I/II Clinical Trial of Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer
15/04/2025
In combination with atezolizumab or durvalumab Study conducted under the CRADA agreement between NCI and Oryzon MADRID and CAMBRIDGE, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: [...]
Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting
15/04/2025
Company to share new preclinical combination data for FHD-909 (LY4050784), a potential first-in-class selective SMARCA2 inhibitor, with non-small cell lung cancer (NSCLC) as the primary target population Additional [...]
Vistin Pharma ASA: Invitation to Q1 2025 conference call
15/04/2025
Oslo, Norway, 15 April 2025 Vistin Pharma ASA (VISTN) will release its first quarter results on Friday 25th of April 2025. Vistin Pharma will host a conference call for all shareholders and interested parties at the [...]
Bluejay Announces Abstract Accepted for Presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting
15/04/2025
New clinical data from the SYMON-I study to evaluate IL-6 in sepsis patients to be presented. ACTON, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX), today announced acceptance of an [...]
Remix Therapeutics Appoints Linda C. Bain to Board of Directors
15/04/2025
WATERTOWN, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers [...]

Pages